DDInter1585 DDInter899
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Reteplase {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Bivalirudin
Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Reteplase may lead to a major life threatening interaction when taken with Edoxaban
Reteplase may lead to a major life threatening interaction when taken with Bivalirudin